{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:02:33Z","timestamp":1790413353966,"version":"4.1.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100023581","name":"National Science Foundation Graduate Research Fellowship Program","doi-asserted-by":"publisher","award":["2024372992"],"award-info":[{"award-number":["2024372992"]}],"id":[{"id":"10.13039\/100023581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["CAT-24-1410062-01-CAT"],"award-info":[{"award-number":["CAT-24-1410062-01-CAT"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006806","name":"Hollings Cancer Center, Medical University of South Carolina","doi-asserted-by":"publisher","award":["Marti's Wish Award"],"award-info":[{"award-number":["Marti's Wish Award"]}],"id":[{"id":"10.13039\/100006806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006806","name":"Hollings Cancer Center, Medical University of South Carolina","doi-asserted-by":"publisher","award":["Dr. Mark Green Young Investigator Award"],"award-info":[{"award-number":["Dr. Mark Green Young Investigator Award"]}],"id":[{"id":"10.13039\/100006806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32 GM132055"],"award-info":[{"award-number":["T32 GM132055"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35 GM119512"],"award-info":[{"award-number":["R35 GM119512"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K22 CA273681"],"award-info":[{"award-number":["K22 CA273681"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006942","name":"Medical University of South Carolina","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006942","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11523-025-01136-6","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T13:55:14Z","timestamp":1740837314000},"page":"281-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Development of ATM Inhibitors in Cancer Therapy"],"prefix":"10.1007","volume":"20","author":[{"given":"Elizabeth A.","family":"Ampolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Jimenez-Sainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-0316","authenticated-orcid":false,"given":"David T.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"issue":"4","key":"1136_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1542\/peds.21.4.526","volume":"21","author":"E Boder","year":"1958","unstructured":"Boder E, Sedgwick RP. Ataxia-telangiectasia: a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics. 1958;21(4):526\u201354.","journal-title":"Pediatrics"},{"key":"1136_CR2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.74218","volume":"11","author":"C Warren","year":"2022","unstructured":"Warren C, Pavletich NP. Structure of the human ATM kinase and mechanism of Nbs1 binding. Elife. 2022;11: e74218.","journal-title":"Elife"},{"issue":"9","key":"1136_CR3","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","volume":"61","author":"KG Pike","year":"2018","unstructured":"Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N, et al. The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6- [3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo [4,5-c]quinolin-2-one). J Med Chem. 2018;61(9):3823\u201341.","journal-title":"J Med Chem"},{"key":"1136_CR4","unstructured":"Schr\u00f6dinger L. The PyMOL molecular graphics system. 3.0.4 ed."},{"issue":"1","key":"1136_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-016-0543-7","volume":"11","author":"C Rothblum-Oviatt","year":"2016","unstructured":"Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016;11(1):1\u201321.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1136_CR6","first-page":"557","volume":"116","author":"JL Morgan","year":"1968","unstructured":"Morgan JL, Holcomb TM, Morrissey RW. Radiation reaction in ataxia telangiectasia. Am J Dis Child. 1968;116(5):557\u20138.","journal-title":"Am J Dis Child"},{"issue":"5","key":"1136_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/09553008114550651","volume":"39","author":"F Zampetti-Bosseler","year":"1981","unstructured":"Zampetti-Bosseler F, Scott D. Cell death, chromosome damage and mitotic delay in normal human, ataxia telangiectasia and retinoblastoma fibroblasts after X-irradiation. Int J Radiat Biol Relat Stud Phys Chem Med. 1981;39(5):547\u201358.","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"issue":"5","key":"1136_CR8","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.3390\/ijms24054741","volume":"24","author":"J Moon","year":"2023","unstructured":"Moon J, Kitty I, Renata K, Qin S, Zhao F, Kim W. DNA damage and its role in cancer therapeutics. Int J Mol Sci. 2023;24(5):4741.","journal-title":"Int J Mol Sci"},{"key":"1136_CR9","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJM198705213162101","volume":"316","author":"M Swift","year":"1987","unstructured":"Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987;316:1289\u201394.","journal-title":"N Engl J Med"},{"issue":"5218","key":"1136_CR10","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1126\/science.7792600","volume":"268","author":"K Savitsky","year":"1995","unstructured":"Savitsky K, Anat B-S, Shlomit G, Galit R, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268(5218):1749\u201353.","journal-title":"Science"},{"issue":"2","key":"1136_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1006\/geno.1996.0201","volume":"33","author":"T Uziel","year":"1996","unstructured":"Uziel T, Savitsky K, Platzer M, Ziv Y, Helbitz T, Nehls M, et al. Genomic organization of the ATM gene. Genomics. 1996;33(2):317\u201320.","journal-title":"Genomics"},{"issue":"5828","key":"1136_CR12","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1140321","volume":"316","author":"S Matsuoka","year":"2007","unstructured":"Matsuoka S, Ballif BA, Smogorzewska A, McDonald Iii ER, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316(5828):1160\u20136.","journal-title":"Science"},{"issue":"11","key":"1136_CR13","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/sj.cdd.4400874","volume":"8","author":"KK Khanna","year":"2001","unstructured":"Khanna KK, Lavin MF, Jackson SP, Mulhern TD. ATM, a central controller of cellular responses to DNA damage. Cell Death Differ. 2001;8(11):1052\u201365.","journal-title":"Cell Death Differ"},{"issue":"6","key":"1136_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 2017;66(6):801\u201317.","journal-title":"Mol Cell"},{"key":"1136_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.793884","author":"SR Kieffer","year":"2022","unstructured":"Kieffer SR, Lowndes NF. Immediate-early, early, and late responses to DNA double stranded breaks. Front Genetics. 2022;13:793884.\u00a0https:\/\/doi.org\/10.3389\/fgene.2022.793884.","journal-title":"Front Genetics"},{"issue":"6922","key":"1136_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nature01368","volume":"421","author":"CJ Bakkenist","year":"2003","unstructured":"Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421(6922):499\u2013506.","journal-title":"Nature"},{"issue":"24","key":"1136_CR17","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1128\/MCB.01382-07","volume":"27","author":"Y Sun","year":"2007","unstructured":"Sun Y, Xu Y, Roy K, Price BD. DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol Cell Biol. 2007;27(24):8502\u20139.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"1136_CR18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.molcel.2017.08.002","volume":"67","author":"LR Myler","year":"2017","unstructured":"Myler LR, Gallardo IF, Soniat MM, Desphande RA, Gonzalez XB, Kim Y, et al. Single-molecule imaging reveals how Mre11-Rad50-Nbs1 initiates DNA break repair. Mol Cell. 2017;67(5):891\u20138.","journal-title":"Mol Cell"},{"issue":"1","key":"1136_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/ijms23010523","volume":"23","author":"S Ueno","year":"2022","unstructured":"Ueno S, Sudo T, Hirasawa A. ATM: functions of ATM Kinase and its relevance to hereditary tumors. Int J Mol Sci. 2022;23(1):523.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"1136_CR20","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1128\/MCB.25.13.5363-5379.2005","volume":"25","author":"Z You","year":"2005","unstructured":"You Z, Chahwan C, Bailis JHT, Russell P. ATM activation and its recruitment to damaged DNA require binding to the C terminus of Nbs1. Mol Cell Biol. 2005;25(23):5363\u201379.","journal-title":"Mol Cell Biol"},{"issue":"7108","key":"1136_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature05112","volume":"443","author":"M Pellegrini","year":"2006","unstructured":"Pellegrini M, Celeste A, Difilippantonio S, Guo R, Wang W, Feigenbaum L, et al. Autophosphorylation at serine 1987 is dispensable for murine ATM activation in vivo. Nature. 2006;443(7108):222\u20135.","journal-title":"Nature"},{"issue":"3","key":"1136_CR22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.4103\/1673-5374.350194","volume":"18","author":"Y Mitiagin","year":"2023","unstructured":"Mitiagin Y, Barzilai A. Ataxia-telangiectasia mutated plays an important role in cerebellar integrity and functionality. Neural Regen Res. 2023;18(3):497\u2013502.","journal-title":"Neural Regen Res"},{"issue":"12","key":"1136_CR23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/35046542","volume":"2","author":"DQ Yang","year":"2000","unstructured":"Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol. 2000;2(12):893\u20138.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"1136_CR24","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1074\/jbc.M410344200","volume":"280","author":"JG Viniegra","year":"2005","unstructured":"Viniegra JG, Mart\u00ednez N, Modirassari P, Losa JH, Cobo CP, Lobo VJS-A, et al. Full activation of PKB\/Akt in response to insulin or ionizing radiation is mediated through ATM*. J Biol Chem. 2005;280(6):4029\u201336.","journal-title":"J Biol Chem"},{"key":"1136_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fped.2020.00317","volume":"8","author":"H Donath","year":"2020","unstructured":"Donath H, Hess U, Kieslich M, Theis M, Ohlenschl\u00e4ger U, Schubert R, et al. Diabetes in patients with ataxia telangiectasia: a national cohort study. Front Pediatr. 2020;8:317.","journal-title":"Front Pediatr"},{"issue":"6","key":"1136_CR26","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2011-08-373639","volume":"119","author":"YA Valentin-Vega","year":"2012","unstructured":"Valentin-Vega YA, Maclean KH, Tait-Mulder J, Milasta S, Steeves M, Dorsey FC, et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood. 2012;119(6):1490\u2013500.","journal-title":"Blood"},{"issue":"9","key":"1136_CR27","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1172\/JCI31604","volume":"117","author":"JS Eaton","year":"2007","unstructured":"Eaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest. 2007;117(9):2723\u201334.","journal-title":"J Clin Invest"},{"issue":"2","key":"1136_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.2014.56.5101","volume":"33","author":"F Suarez","year":"2015","unstructured":"Suarez F, Mahlaoui N, Canioni D, Andriamanga C, d\u2019Enghien CD, Brousse N, et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French National Registry of Primary Immune Deficiencies. J Clin Oncol. 2015;33(2):202\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1136_CR29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjh.17736","volume":"194","author":"S Bakhtiar","year":"2021","unstructured":"Bakhtiar S, Salzmann-Manrique E, Donath H, Woelke S, Duecker RP, Fritzemeyer S, et al. The incidence and type of cancer in patients with ataxia-telangiectasia via a retrospective single-centre study. Br J Haematol. 2021;194(5):879\u201387.","journal-title":"Br J Haematol"},{"issue":"1","key":"1136_CR30","first-page":"89","volume":"77","author":"D Morrell","year":"1986","unstructured":"Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst. 1986;77(1):89\u201392.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1136_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","volume":"14","author":"MJ Hall","year":"2021","unstructured":"Hall MJ, Bernhisel R, Hughes E, Larson K, Rosenthal ET, Singh NA, et al. Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers | Cancer Prevention Research | American Association for Cancer Research. Cancer Prev Res. 2021;14(4):433\u201340.","journal-title":"Cancer Prev Res"},{"issue":"26","key":"1136_CR32","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1056\/NEJM199112263252602","volume":"325","author":"M Swift","year":"1991","unstructured":"Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991;325(26):1831\u20136.","journal-title":"N Engl J Med"},{"issue":"21","key":"1136_CR33","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJM198705213162101","volume":"316","author":"M Swift","year":"1987","unstructured":"Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987;316(21):1289\u201394.","journal-title":"N Engl J Med"},{"issue":"8","key":"1136_CR34","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","volume":"15","author":"M Choi","year":"2016","unstructured":"Choi M, Kipps T, Kurzrock R. ATM mutations in cancer: therapeutic implications. Mol Cancer Ther. 2016;15(8):1781\u201391.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1136_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"269","key":"1136_CR36","doi-asserted-by":"publisher","first-page":"pl1-pl","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1-pl.","journal-title":"Sci Signal"},{"issue":"23","key":"1136_CR37","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83(23):3861\u20137.","journal-title":"Cancer Res"},{"issue":"2","key":"1136_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nbt.3391","volume":"34","author":"MT Chang","year":"2016","unstructured":"Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34(2):155\u201363.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"1136_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","volume":"8","author":"MT Chang","year":"2018","unstructured":"Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. 2018;8(2):174\u201383.","journal-title":"Cancer Discov"},{"issue":"9\u201310","key":"1136_CR40","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/smll.201201510","volume":"9","author":"R Xu","year":"2013","unstructured":"Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, et al. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small. 2013;9(9\u201310):1799\u2013808.","journal-title":"Small"},{"issue":"1","key":"1136_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3892\/or.2017.5665","volume":"38","author":"Y Li","year":"2017","unstructured":"Li Y, Li L, Wu Z, Wang L, Wu Y, Li D, et al. Silencing of ATM expression by siRNA technique contributes to glioma stem cell radiosensitivity in vitro and in vivo. Oncol Rep. 2017;38(1):325\u201335.","journal-title":"Oncol Rep"},{"issue":"24","key":"1136_CR42","doi-asserted-by":"publisher","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","volume":"64","author":"I Hickson","year":"2004","unstructured":"Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NMB, Orr AI, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Can Res. 2004;64(24):9152\u20139.","journal-title":"Can Res"},{"issue":"10","key":"1136_CR43","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-09-0519","volume":"8","author":"SE Golding","year":"2009","unstructured":"Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Therapy. 2009;8(10):2894\u2013902.","journal-title":"Mol Cancer Therapy."},{"issue":"18","key":"1136_CR44","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-0763","volume":"68","author":"MD Rainey","year":"2008","unstructured":"Rainey MD, Charlton ME, Stanton RV, Kastan MB. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 2008;68(18):7466\u201374.","journal-title":"Cancer Res"},{"issue":"13","key":"1136_CR45","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jmedchem.6b00519","volume":"59","author":"SL Degorce","year":"2016","unstructured":"Degorce SL, Barlaam B, Cadogan E, Dishington A, Ducray R, Glossop SC, et al. Discovery of novel 3-quinoline carboxamides as potent, selective, and orally bioavailable inhibitors of ataxia telangiectasia mutated (ATM) kinase. J Med Chem. 2016;59(13):6281\u201392.","journal-title":"J Med Chem"},{"issue":"6","key":"1136_CR46","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/1535-7163.MCT-12-0707","volume":"12","author":"MA Batey","year":"2013","unstructured":"Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NMB, et al. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer | Molecular Cancer Therapeutics | American Association for Cancer Research. Mol Cancer Ther. 2013;12(6):959\u201367.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1136_CR47","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","volume":"21","author":"A Zimmermann","year":"2022","unstructured":"Zimmermann A, Zenke FT, Chiu L-Y, Dahmen H, Pehl U, Fuchss T, et al. A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies. Mol Cancer Ther. 2022;21(6):859\u201370.","journal-title":"Mol Cancer Ther"},{"issue":"67","key":"1136_CR48","doi-asserted-by":"publisher","first-page":"110904","DOI":"10.18632\/oncotarget.22920","volume":"8","author":"J Greene","year":"2017","unstructured":"Greene J, Nguyen A, Bagby SM, Jones GN, Tai W, Quackenbush KS, et al. The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy. Oncotarget. 2017;8(67):110904\u201313.","journal-title":"Oncotarget"},{"issue":"1","key":"1136_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.yexcr.2018.03.006","volume":"366","author":"K Li","year":"2018","unstructured":"Li K, Yan H, Guo W, Tang M, Zhao X, Tong A, et al. ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin. Exp Cell Res. 2018;366(1):24\u201333.","journal-title":"Exp Cell Res"},{"key":"1136_CR50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-3-319-75836-7_8","volume-title":"Targeting the DNA damage response for anti-cancer therapy","author":"I Hickson","year":"2018","unstructured":"Hickson I, Pike KG, Durant ST. Targeting ATM for cancer therapy: prospects for drugging ATM. In: Pollard J, Curtin N, editors. Targeting the DNA damage response for anti-cancer therapy. Cham: Springer International Publishing; 2018. p. 185\u2013208."},{"issue":"10","key":"1136_CR51","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18(10):610\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"1136_CR52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.gpb.2016.05.001","volume":"14","author":"H Wei","year":"2016","unstructured":"Wei H, Yu X. Functions of PARylation in DNA damage repair pathways. Genom Proteomics Bioinform. 2016;14(3):131\u20139.","journal-title":"Genom Proteomics Bioinform"},{"issue":"4","key":"1136_CR53","doi-asserted-by":"publisher","first-page":"405","DOI":"10.32604\/or.2023.028310","volume":"31","author":"DK Nambiar","year":"2023","unstructured":"Nambiar DK, Mishra D, Singh RP. Targeting DNA repair for cancer treatment: lessons from PARP inhibitor trials. Oncol Res. 2023;31(4):405\u201321.","journal-title":"Oncol Res"},{"key":"1136_CR54","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","volume":"149","author":"AM Weber","year":"2015","unstructured":"Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol Ther. 2015;149:124\u201338.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1136_CR55","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.trecan.2020.10.010","volume":"7","author":"KE Baillie","year":"2021","unstructured":"Baillie KE, Stirling PC. Beyond kinases: targeting replication stress proteins in cancer therapy. Trends Cancer. 2021;7(5):430\u201346.","journal-title":"Trends Cancer"},{"issue":"1","key":"1136_CR56","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","volume":"16","author":"MK Zeman","year":"2014","unstructured":"Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014;16(1):2\u20139.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"1136_CR57","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1111\/cas.15845","volume":"114","author":"K Yano","year":"2023","unstructured":"Yano K, Shiotani B. Emerging strategies for cancer therapy by ATR inhibitors. Cancer Sci. 2023;114(7):2709\u201321.","journal-title":"Cancer Sci"},{"key":"1136_CR58","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0440","author":"J Zhang","year":"2024","unstructured":"Zhang J, Yu S, Peng Q, Wang P, Fang L. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies. Cancer Biol Med. 2024;21(1):45-64.\u00a0https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0440.","journal-title":"Cancer Biol Med"},{"key":"1136_CR59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139333","author":"M Hu","year":"2021","unstructured":"Hu M, Zhou M, Bao X, Pan D, Jiao M, Liu X, et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation. J Clin Investig. 2021;131(3):e139333.\u00a0https:\/\/doi.org\/10.1172\/JCI139333.","journal-title":"J Clin Investig"},{"issue":"10","key":"1136_CR60","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1177\/08853282231162111","volume":"37","author":"D Yu","year":"2023","unstructured":"Yu D, Wang H, Liu H, Xu R. Liposomal ATM siRNA delivery for enhancing triple-negative breast cancer immune checkpoint blockade therapy. J Biomater Appl. 2023;37(10):1835\u201346.","journal-title":"J Biomater Appl"},{"issue":"3","key":"1136_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1083\/jcb.201207063","volume":"198","author":"Y Shiloh","year":"2012","unstructured":"Shiloh Y, Ziv Y. The ATM protein: the importance of being active. J Cell Biol. 2012;198(3):273\u20135.","journal-title":"J Cell Biol"},{"issue":"3","key":"1136_CR62","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1083\/jcb.201204098","volume":"198","author":"K Yamamoto","year":"2012","unstructured":"Yamamoto K, Wang Y, Jiang W, Liu X, Dubois RL, Lin CS, et al. Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice. J Cell Biol. 2012;198(3):305\u201313.","journal-title":"J Cell Biol"},{"key":"1136_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-020-0376-x","author":"D Menolfi","year":"2020","unstructured":"Menolfi D, Zha S. ATM, ATR and DNA-PKcs kinases\u2014the lessons from the mouse models: inhibition \u2260 deletion. Cell Biosci. 2020;10:8.\u00a0https:\/\/doi.org\/10.1186\/s13578-020-0376-x.","journal-title":"Cell Biosci"},{"issue":"3","key":"1136_CR64","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1083\/jcb.201204035","volume":"198","author":"JA Daniel","year":"2012","unstructured":"Daniel JA, Pellegrini M, Lee B-S, Guo Z, Filsuf D, Belkina NV, et al. Loss of ATM kinase activity leads to embryonic lethality in mice. J Cell Biol. 2012;198(3):295\u2013304.","journal-title":"J Cell Biol"},{"issue":"20","key":"1136_CR65","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.4161\/cc.9.20.13471","volume":"9","author":"S Choi","year":"2010","unstructured":"Choi S, Gamper AM, White JS, Bakkenist CJ. Inhibition of ATM kinase activity does not phenocopy ATM protein disruption. Cell Cycle. 2010;9(20):4052\u20137.","journal-title":"Cell Cycle"},{"issue":"124","key":"1136_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2000758","volume":"3","author":"JS White","year":"2010","unstructured":"White JS, Choi S, Bakkenist CJ. Transient ATM kinase inhibition disrupts DNA damage-induced sister chromatid exchange. Sci Signal. 2010;3(124): ra44.","journal-title":"Sci Signal"},{"issue":"10","key":"1136_CR67","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41594-021-00654-x","volume":"28","author":"K Stakyte","year":"2021","unstructured":"Stakyte K, Rotheneder M, Lammens K, Bartho JD, Gr\u00e4dler U, Fuch\u00df T, et al. Molecular basis of human ATM kinase inhibition. Nat Struct Mol Biol. 2021;28(10):789\u201398.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"1136_CR68","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1158\/1535-7163.MCT-08-1189","volume":"9","author":"Y Li","year":"2010","unstructured":"Li Y, Yang D-Q. The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt. Mol Cancer Ther. 2010;9(1):113\u201325.","journal-title":"Mol Cancer Ther"},{"key":"1136_CR69","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001415RR","author":"BRE Harris","year":"2021","unstructured":"Harris BRE, Zhang Y, Tao J, Shen R, Zhao X, Cleary MP, et al. ATM inhibitor KU-55933 induces apoptosis and inhibits motility by blocking GLUT1-mediated glucose uptake in aggressive cancer cells with sustained activation of Akt. FASEB J. 2021;35(4):e21264. https:\/\/doi.org\/10.1096\/fj.202001415RR.","journal-title":"FASEB J"},{"key":"1136_CR70","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biocel.2017.03.015","volume":"87","author":"J Chwastek","year":"2017","unstructured":"Chwastek J, Jantas D, Laso\u0144 W. The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide-induced cell damage via a \u03b3H2AX\/p-p53\/caspase-3-independent mechanism: inhibition of calpain and cathepsin D. Int J Biochem Cell Biol. 2017;87:38\u201353.","journal-title":"Int J Biochem Cell Biol"},{"issue":"47","key":"1136_CR71","doi-asserted-by":"publisher","first-page":"20211","DOI":"10.1039\/C5NR05869D","volume":"7","author":"X Tian","year":"2015","unstructured":"Tian X, Lara H, Wagner KT, Saripalli S, Hyder SN, Foote M, et al. Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery. Nanoscale. 2015;7(47):20211\u20139.","journal-title":"Nanoscale"},{"key":"1136_CR72","doi-asserted-by":"crossref","unstructured":"Reinecke M, Heinzlmeir S, Wilhelm M, M\u00e9dard G, Klaeger S, Kuster B. Kinobeads: a chemical proteomic approach for kinase inhibitor selectivity profiling and target discovery. Target Discovery and Validation, 2019; pp. 97\u2013130.","DOI":"10.1002\/9783527818242.ch4"},{"issue":"4","key":"1136_CR73","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1021\/acschembio.8b01020","volume":"14","author":"M Reinecke","year":"2019","unstructured":"Reinecke M, Ruprecht B, Poser S, Wiechmann S, Wilhelm M, Heinzlmeir S, et al. Chemoproteomic selectivity profiling of PIKK and PI3K kinase inhibitors. ACS Chem Biol. 2019;14(4):655\u201364.","journal-title":"ACS Chem Biol"},{"issue":"4","key":"1136_CR74","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1177\/1087057113520325","volume":"19","author":"K Guo","year":"2014","unstructured":"Guo K, Shelat AA, Guy RK, Kastan MB. Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors. SLAS Discovery. 2014;19(4):538\u201346.","journal-title":"SLAS Discovery."},{"issue":"7","key":"1136_CR75","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1177\/1087057112448529","volume":"17","author":"C Bardelle","year":"2012","unstructured":"Bardelle C, Boros J. Development of a high-content high-throughput screening assay for the discovery of ATM signaling inhibitors. SLAS Discovery. 2012;17(7):912\u201320.","journal-title":"SLAS Discovery."},{"issue":"2","key":"1136_CR76","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ijc.28680","volume":"135","author":"D Vecchio","year":"2014","unstructured":"Vecchio D, Daga A, Carra E, Marubbi D, Baio G, Neumaier CE, et al. Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019. Int J Cancer. 2014;135(2):479\u201391.","journal-title":"Int J Cancer"},{"issue":"3","key":"1136_CR77","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/cancers15030735","volume":"15","author":"Y Tozaki","year":"2023","unstructured":"Tozaki Y, Aoki H, Kato R, Toriuchi K, Arame S, Inoue Y, et al. The combination of ATM and Chk1 inhibitors induces synthetic lethality in colorectal cancer cells. Cancers. 2023;15(3):735.","journal-title":"Cancers"},{"issue":"12","key":"1136_CR78","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-12-3408","volume":"19","author":"L Biddlestone-Thorpe","year":"2013","unstructured":"Biddlestone-Thorpe L, Sajjad M, Rosenberg E, Beckta JM, Valerie NCK, Tokarz M, et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation | Clinical Cancer Research | American Association for Cancer Research. Clin Cancer Res. 2013;19(12):3189\u201332000.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1136_CR79","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3390\/biom12040548","volume":"12","author":"S Zhang","year":"2022","unstructured":"Zhang S, Carlsen L, Hernandez Borrero L, Seyhan AA, Tian X, El-Deiry WS. Advanced strategies for therapeutic targeting of wild-type and mutant p53 in cancer. Biomolecules. 2022;12(4):548.","journal-title":"Biomolecules"},{"issue":"16","key":"1136_CR80","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1101\/gad.1815309","volume":"23","author":"H Jiang","year":"2009","unstructured":"Jiang H, Reinhardt CH, Bartkova I, Tommiska J, Blomqvist C, Nevanlinna H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009;23(16):1895\u2013909.","journal-title":"Genes Dev"},{"issue":"8","key":"1136_CR81","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1158\/1535-7163.MCT-17-0975","volume":"17","author":"J Karlin","year":"2018","unstructured":"Karlin J, Allen J, Ahmad SF, Hughes G, Sheridan V, Odedra R, et al. Orally bioavailable and blood\u2013brain barrier-penetrating atm inhibitor (AZ32) radiosensitizes intracranial gliomas in mice. Mol Cancer Ther. 2018;17(8):1637\u201347.","journal-title":"Mol Cancer Ther"},{"key":"1136_CR82","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jpba.2017.01.055","volume":"138","author":"BF Kiesel","year":"2017","unstructured":"Kiesel BF, Shogan JC, Rachid M, Parise RA, Vendetti FP, Bakkenist CJ, et al. LC\u2013MS\/MS assay for the simultaneous quantitation of the ATM inhibitor AZ31 and the ATR inhibitor AZD6738 in mouse plasma. J Pharm Biomed Anal. 2017;138:158\u201365.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"1136_CR83","doi-asserted-by":"publisher","first-page":"E600","DOI":"10.1016\/j.ijrobp.2017.06.2046","volume":"99","author":"J Kahn","year":"2017","unstructured":"Kahn J, Allen J, Karlin JD, Ahmad S, Sule A, Tokarz M, et al. Next-Generation ATM kinase inhibitors under development radiosensitize glioblastoma with conformal radiation in a mouse orthotopic model. Int J Radiat Oncol Biol Phys. 2017;99(2):E600\u20131.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1136_CR84","doi-asserted-by":"publisher","first-page":"41892","DOI":"10.1038\/srep41892","volume":"7","author":"FP Vendetti","year":"2017","unstructured":"Vendetti FP, Leibowitz BJ, Barnes J, Schamus S, Kiesel BF, Abberbock S, et al. Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation. Sci Rep. 2017;7(1):41892.","journal-title":"Sci Rep"},{"issue":"14_supplement","key":"1136_CR85","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1158\/1538-7445.AM2016-3041","volume":"76","author":"ST Durant","year":"2016","unstructured":"Durant ST, Karlin J, Pike K, Colclough N, Mukhopadhyay N, Ahmad SF, et al. Abstract 3041: Blood\u2013brain barrier penetrating ATM inhibitor (AZ32) radiosensitises intracranial gliomas in mice. Cancer Res. 2016;76(14_supplement):3041.","journal-title":"Cancer Res"},{"key":"1136_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.680663","author":"K Liu","year":"2021","unstructured":"Liu K, Li Y-C, Chen Y, Shi X-B, Xing Z-H, He Z-J, et al. AZ32 reverses ABCG2-mediated multidrug resistance in colorectal cancer. Front Oncol. 2021;11:680663.\u00a0https:\/\/doi.org\/10.3389\/fonc.2021.680663.","journal-title":"Front Oncol"},{"issue":"1","key":"1136_CR87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10555-007-9042-6","volume":"26","author":"RW Robey","year":"2007","unstructured":"Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007;26(1):39\u201357.","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"1136_CR88","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1158\/1535-7163.MCT-20-0502","volume":"20","author":"SJ Gill","year":"2021","unstructured":"Gill SJ, Wijnhoven PWG, Fok JHL, Lloyd RL, Cairns J, Armenia J, et al. Radiopotentiation profiling of multiple inhibitors of the dna damage response for early clinical development. Mol Cancer Ther. 2021;20(9):1614\u201326.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"1136_CR89","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s00066-022-02009-x","volume":"199","author":"J Scheper","year":"2023","unstructured":"Scheper J, Hildebrand LS, Faulhaber E-M, Deloch L, Gaipl US, Symank J, et al. Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts. Strahlenther Onkol. 2023;199(12):1128\u201339.","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"1136_CR90","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","volume":"19","author":"LC Riches","year":"2020","unstructured":"Riches LC, Trinidad AG, Hughes G, Jones GN, Hughes AM, Thomason AG, et al. Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically. Mol Cancer Ther. 2020;19(1):13\u201325.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1136_CR91","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/genes12060925","volume":"12","author":"E-M Faulhaber","year":"2021","unstructured":"Faulhaber E-M, Jost T, Symank J, Scheper J, B\u00fcrkel F, Fietkau R, et al. Kinase inhibitors of DNA-PK, ATM and ATR in combination with ionizing radiation can increase tumor cell death in HNSCC cells while sparing normal tissue cells. Genes. 2021;12(6):925.","journal-title":"Genes"},{"issue":"1","key":"1136_CR92","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1186\/s12885-022-10084-7","volume":"22","author":"SL Davis","year":"2022","unstructured":"Davis SL, Hartman SJ, Bagby SM, Schlaepfer M, Yacob BW, Tse T, et al. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. BMC Cancer. 2022;22(1):1107.","journal-title":"BMC Cancer"},{"issue":"1","key":"1136_CR93","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.1038\/s41467-023-42831-0","volume":"14","author":"I Rosso","year":"2023","unstructured":"Rosso I, Jones-Weinert C, Rossiello F, Cabrini M, Brambillasca S, Munoz-Sagredo L, et al. Alternative lengthening of telomeres (ALT) cells viability is dependent on C-rich telomeric RNAs. Nat Commun. 2023;14(1):7086.","journal-title":"Nat Commun"},{"issue":"607","key":"1136_CR94","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd5750","volume":"13","author":"B Koneru","year":"2021","unstructured":"Koneru B, Farooqi A, Nguyen TH, Chen WH, Hindle A, Eslinger C, et al. ALT neuroblastoma chemoresistance due to telomere dysfunction\u2013induced ATM activation is reversible with ATM inhibitor AZD0156. Sci Transl Med. 2021;13(607): eabd5750.","journal-title":"Sci Transl Med"},{"issue":"9","key":"1136_CR95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007474","volume":"11","author":"WJ Jin","year":"2023","unstructured":"Jin WJ, Zangl LM, Hyun M, Massoud E, Schroeder K, Alexandridis RA, et al. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models. J Immunother Cancer. 2023;11(9): e007474.","journal-title":"J Immunother Cancer"},{"issue":"15","key":"1136_CR96","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.3390\/cancers14153794","volume":"14","author":"W-K Wong","year":"2022","unstructured":"Wong W-K, Guerra Liberal FDC, McMahon SJ. DNA repair inhibitors potentiate fractionated radiotherapy more than single-dose radiotherapy in breast cancer cells. Cancers. 2022;14(15):3794.","journal-title":"Cancers"},{"issue":"13","key":"1136_CR97","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1158\/1538-7445.AM2018-4909","volume":"78","author":"Y Chen","year":"2018","unstructured":"Chen Y, Pass M, Bruna NB, Stephens C, Pierce A, Hanekom W, et al. Abstract 4909: adaptive oncology phase 1 study of first-in-class inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib. Cancer Res. 2018;78(13):4909.","journal-title":"Cancer Res"},{"key":"1136_CR98","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat1719","author":"ST Durant","year":"2018","unstructured":"Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018;4(6)eaat1719.\u00a0https:\/\/doi.org\/10.1126\/sciadv.aat1719.","journal-title":"Sci Adv"},{"issue":"21","key":"1136_CR99","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1158\/1078-0432.CCR-23-0290","volume":"29","author":"BY Tew","year":"2023","unstructured":"Tew BY, Kalfa AJ, Yang Z, Hurth KM, Simon T, Abnoosian E, et al. ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis. Clin Cancer Res. 2023;29(21):4492\u2013503.","journal-title":"Clin Cancer Res"},{"key":"1136_CR100","doi-asserted-by":"crossref","unstructured":"Ran X, Wu BX, Shi M, Song L, Nixon K, Philip V et al. CRISPR screen of druggable targets in small cell lung cancer identified ATM inhibitor (AZD1390) as a radiosensitizer. Int J Radiat Oncol Biol Phys. 2024;118(5):1308\u20131314.","DOI":"10.1016\/j.ijrobp.2023.12.011"},{"issue":"10","key":"1136_CR101","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/neuonc\/noad064","volume":"25","author":"J Xie","year":"2023","unstructured":"Xie J, Kuriakose T, Bianski B, Twarog N, Savage E, Xu K, et al. ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma. Neuro Oncol. 2023;25(10):1828\u201341.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1136_CR102","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1038\/s41467-024-49316-8","volume":"15","author":"DJ Laverty","year":"2024","unstructured":"Laverty DJ, Gupta SK, Bradshaw GA, Hunter AS, Carlson BL, Calmo NM, et al. ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma. Nat Commun. 2024;15(1):5294.","journal-title":"Nat Commun"},{"issue":"1","key":"1136_CR103","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1124\/jpet.122.001230","volume":"383","author":"S Talele","year":"2022","unstructured":"Talele S, Zhang W, Chen J, Gupta SK, Burgenske DM, Sarkaria JN, et al. Central nervous system distribution of the ataxia-telangiectasia mutated kinase inhibitor AZD1390: implications for the treatment of brain tumors. J Pharmacol Exp Ther. 2022;383(1):91\u2013102.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1136_CR104","doi-asserted-by":"publisher","first-page":"981","DOI":"10.7150\/ijbs.79852","volume":"19","author":"S Zheng","year":"2023","unstructured":"Zheng S, Song J, Linghu D, Yang R, Liu B, Xue Z, et al. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity. Int J Biol Sci. 2023;19(3):981\u201393.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"1136_CR105","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/noaa238","volume":"23","author":"A Jucaite","year":"2021","unstructured":"Jucaite A, Stenkrona P, Csel\u00e9nyi Z, De Vita S, Buil-Bruna N, Varn\u00e4s K, et al. Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study. Neuro Oncol. 2021;23(4):687\u201396.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1136_CR106","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13550-022-00920-z","volume":"12","author":"CR Fraser","year":"2022","unstructured":"Fraser CR, Ajenjo J, Veal M, Dias GM, Chan C, O\u2019Neill E, et al. Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent. EJNMMI Res. 2022;12(1):50.","journal-title":"EJNMMI Res"},{"issue":"3","key":"1136_CR107","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.clon.2009.12.003","volume":"22","author":"A Martin","year":"2010","unstructured":"Martin A, Gaya A. Stereotactic body radiotherapy: a review. Clin Oncol. 2010;22(3):157\u201372.","journal-title":"Clin Oncol"},{"key":"1136_CR108","first-page":"61","volume":"25","author":"GM Walls","year":"2020","unstructured":"Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, et al. CONCORDE: a phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clin Transl Radiat Oncol. 2020;25:61\u20136.","journal-title":"Clin Transl Radiat Oncol."},{"issue":"6","key":"1136_CR109","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.clon.2020.02.003","volume":"32","author":"C Faivre-Finn","year":"2020","unstructured":"Faivre-Finn C, Brown S, Ryan A, Greystoke A. The UK at the forefront of innovative drug-radiotherapy combination clinical trials: introducing the CONCORDE Platform. Clin Oncol. 2020;32(6):358\u201362.","journal-title":"Clin Oncol"},{"issue":"13_Supplement","key":"1136_CR110","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1538-7445.AM2018-338","volume":"78","author":"A Zimmermann","year":"2018","unstructured":"Zimmermann A, Zenke F, Dahmen H, Sirrenberg C, Grombacher T, Vassilev LT, et al. Abstract 338: a new investigational ATM Inhibitor, M3541, synergistically potentiates fractionated radiotherapy and chemotherapy in cancer cells and animal models. Cancer Res. 2018;78(13_Supplement):338.","journal-title":"Cancer Res"},{"issue":"2","key":"1136_CR111","doi-asserted-by":"publisher","first-page":"492","DOI":"10.18632\/aging.204487","volume":"15","author":"L-Y Chiu","year":"2023","unstructured":"Chiu L-Y, Sun Q, Zenke FT, Blaukat A, Vassilev LT. Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death. Aging. 2023;15(2):492\u2013512.","journal-title":"Aging"},{"issue":"7","key":"1136_CR112","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1535-7163.MCT-22-0685","volume":"22","author":"A Turchick","year":"2023","unstructured":"Turchick A, Zimmermann A, Chiu L-Y, Dahmen H, Elenbaas B, Zenke FT, et al. Selective inhibition of ATM-dependent double-strand break repair and checkpoint control synergistically enhances the efficacy of ATR inhibitors. Mol Cancer Ther. 2023;22(7):859\u201372.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1136_CR113","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s10637-022-01216-8","volume":"40","author":"SN Waqar","year":"2022","unstructured":"Waqar SN, Robinson C, Olszanski AJ, Spira A, Hackmaster M, Lucas L, et al. Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors. Invest New Drugs. 2022;40(3):596\u2013605.","journal-title":"Invest New Drugs"},{"issue":"13_Supplement","key":"1136_CR114","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1158\/1538-7445.AM2019-3500","volume":"79","author":"T Fuchss","year":"2019","unstructured":"Fuchss T, Graedler U, Schiemann K, Kuhn D, Kubas H, Dahmen H, et al. Abstract 3500: highly potent and selective ATM kinase inhibitor M4076: a clinical candidate drug with strong anti-tumor activity in combination therapies. Cancer Res. 2019;79(13_Supplement):3500.","journal-title":"Cancer Res"},{"issue":"20","key":"1136_CR115","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1021\/acs.accounts.2c00500","volume":"55","author":"M Basilaia","year":"2022","unstructured":"Basilaia M, Chen MH, Secka J, Gustafson JL. Atropisomerism in the pharmaceutically relevant realm. Acc Chem Res. 2022;55(20):2904\u201319.","journal-title":"Acc Chem Res"},{"issue":"1","key":"1136_CR116","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.xphs.2021.10.011","volume":"111","author":"C Saal","year":"2022","unstructured":"Saal C, Becker A, Krier M, Fuch\u00df T. Atropisomerism\u2014a neglected way to escape out of solubility flatlands. J Pharm Sci. 2022;111(1):206\u201313.","journal-title":"J Pharm Sci"},{"issue":"8_Supplement","key":"1136_CR117","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT171","volume":"83","author":"LL Siu","year":"2023","unstructured":"Siu LL, Yap TA, Genta S, Pennock G, Hicking C, You X, et al. Abstract CT171: a first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A results. Cancer Res. 2023;83(8_Supplement): CT171.","journal-title":"Cancer Res"},{"issue":"6_Supplement","key":"1136_CR118","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1538-7445.AM2024-7127","volume":"84","author":"D Zhou","year":"2024","unstructured":"Zhou D, Wang Z, Liu Y, Fu T, Cheng Z. Abstract 7127: an ATM inhibitor: ZN-B-2262 in combination with radiation\/ADCs containing topoisomerase inhibitors for the treatment of solid tumors. Cancer Res. 2024;84(6_Supplement):7127.","journal-title":"Cancer Res"},{"key":"1136_CR119","unstructured":"2023 Q3 Results [press release]. CSPC Pharmaceutical Group Limited 2023."},{"key":"1136_CR120","unstructured":"Selective ATM Inhibitor SYH2051 Obtains Clinical Trial Approval [press release]. CSPC Pharmaceutical Group Limited 2023."},{"issue":"12_Supplement","key":"1136_CR121","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1158\/1538-7445.AM2022-3305","volume":"82","author":"AM Tuma","year":"2022","unstructured":"Tuma AM, Zhong W, Liu L, Burgenske DM, Carlson BL, Bakken KK, et al. Abstract 3305: WSD-0628, a novel brain penetrant ATM inhibitor, radiosensitizes GBM and melanoma patient derived xenografts. Cancer Res. 2022;82(12_Supplement):3305.","journal-title":"Cancer Res"},{"issue":"6","key":"1136_CR122","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab196.309","volume":"23","author":"W Zhong","year":"2021","unstructured":"Zhong W, Liu L, Sun C, Mu Z. DDRE-25. WSD0628: a brain penetrable ATM inhibitor as a radiosensitizer for the treatment of GBM and metastatic CNS tumor. Neuro-Oncol. 2021;23(6): vi79-vi.","journal-title":"Neuro-Oncol"},{"key":"1136_CR123","doi-asserted-by":"crossref","unstructured":"Rathi S, Oh J-H, Zhang W, Mladek AC, Garcia DA, Xue Z, et al. Preclinical systemic pharmacokinetics, dose-proportionality, and CNS distribution of the ATM inhibitor WSD0628, a novel radiosensitizer for the treatment of brain tumors. J Pharmacol Exp Ther. 2024;JPET-AR-2023-001971.","DOI":"10.1124\/jpet.123.001971"},{"key":"1136_CR124","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/S0140-6736(15)60373-7","volume":"385","author":"M Kwok","year":"2015","unstructured":"Kwok M, Davies N, Agathanggelou A, Smith E, Petermann E, Yates E, et al. Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. The Lancet. 2015;385:S58.","journal-title":"The Lancet"},{"issue":"21","key":"1136_CR125","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","volume":"21","author":"LM Karnitz","year":"2015","unstructured":"Karnitz LM, Zou L. Molecular pathways: targeting ATR in cancer therapy. Clin Cancer Res. 2015;21(21):4780\u20135.","journal-title":"Clin Cancer Res"},{"issue":"29","key":"1136_CR126","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1073\/pnas.1706392114","volume":"114","author":"C-C Chen","year":"2017","unstructured":"Chen C-C, Kass EM, Yen W-F, Ludwig T, Moynahan ME, Chaudhuri J, et al. ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair. Proc Natl Acad Sci. 2017;114(29):7665\u201370.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"1136_CR127","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0960-9822(01)00048-3","volume":"11","author":"KE Gurley","year":"2001","unstructured":"Gurley KE, Kemp CJ. Synthetic lethality between mutation in ATM and DNA-PKcs during murine embryogenesis. Curr Biol. 2001;11(3):191\u20134.","journal-title":"Curr Biol"},{"issue":"32","key":"1136_CR128","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/s41388-022-02384-w","volume":"41","author":"K-S Oh","year":"2022","unstructured":"Oh K-S, Nam A-R, Bang J-H, Seo H-R, Kim J-M, Yoon J, et al. A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers. Oncogene. 2022;41(32):3939\u201352.","journal-title":"Oncogene"},{"key":"1136_CR129","unstructured":"XRad therapeutics announces first patient dosed in phase 1a clinical trial of XRD-0394 for metastatic, locally-advanced or recurrent solid tumors | BioSpace [press release]. BioSpace.com: BioSpace2021."},{"issue":"6","key":"1136_CR130","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/1535-7163.MCT-23-0890","volume":"23","author":"TM Gilmer","year":"2024","unstructured":"Gilmer TM, Lai C-H, Guo K, Deland K, Ashcraft KA, Stewart AE, et al. A novel dual ATM\/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors. Mol Cancer Ther. 2024;23(6):751\u201365.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1136_CR131","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/j.celrep.2020.01.052","volume":"30","author":"M-Y Cai","year":"2020","unstructured":"Cai M-Y, Dunn CE, Chen W, Kochupurakkal BS, Nguyen H, Moreau LA, et al. Cooperation of the ATM and Fanconi anemia\/BRCA pathways in double-strand break end resection. Cell Rep. 2020;30(7):2402-15.e5.","journal-title":"Cell Rep"},{"issue":"6","key":"1136_CR132","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrm.2016.48","volume":"17","author":"R Ceccaldi","year":"2016","unstructured":"Ceccaldi R, Sarangi P, D\u2019Andrea AD. The Fanconi anaemia pathway: new players and new functions. Nat Rev Mol Cell Biol. 2016;17(6):337\u201349.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7035","key":"1136_CR133","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.","journal-title":"Nature"},{"key":"1136_CR134","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2147\/OTT.S426923","volume":"16","author":"A Zhang","year":"2023","unstructured":"Zhang A, Liqin Z, Xie X, Liu D. Inhibtion of ATM with KU-55933 sensitizes endometrial cancer cell lines to olaparib. OncoTargets Ther. 2023;16:1061\u201371.","journal-title":"OncoTargets Ther"},{"issue":"10","key":"1136_CR135","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1002\/ijc.27512","volume":"131","author":"R Sultana","year":"2012","unstructured":"Sultana R, McNeill DR, Abbotts R, Mohammed MZ, Zdzienicka MZ, Qutob H, et al. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic\/apyrimidinic endonuclease inhibitors. Int J Cancer. 2012;131(10):2433\u201344.","journal-title":"Int J Cancer"},{"key":"1136_CR136","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.critrevonc.2019.04.015","volume":"138","author":"G Frosina","year":"2019","unstructured":"Frosina G, Marubbi D, Marcello D, Vecchio D, Daga A. The efficacy and toxicity of ATM inhibition in glioblastoma initiating cells-driven tumor models. Crit Rev Oncol Hematol. 2019;138:214\u201322.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01136-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01136-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01136-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T03:40:39Z","timestamp":1743306039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01136-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01136-6","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"18 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by the Carolinas Consortium. This work was supported in part by a National Science Foundation Graduate Research Fellowship under grant no. 2024372992 (E.A.A.), a Catalyst Award from the American Cancer Society CAT-24-1410062-01-CAT (D.T.L.), the MUSC Hollings Cancer Center Marti\u2019s Wish Award (J.J.S.) and Dr. Mark Green Young Investigator Award (JJS), and the National Institutes of Health T32 GM132055 (E.A.A.), K22 CA273681 (J.J.S.), and R35 GM119512 (D.T.L.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"E.A.A., J.J.S., and D.T.L. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors consent to publication of this manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analyzed during this study are included in this published article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: E.A.A. and D.T.L.; writing\u2014original draft: E.A.A. and D.T.L.; and writing\u2014reviewing and editing: E.A.A., J.J.S., and D.T.L.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}